Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 16;8(2):e001510. doi: 10.1136/jitc-2020-001510

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The composition of antibody targets changes with clinical stage of disease. (A) Principal component analysis plot obtained by using the set of 13 279 significantly changed peptides identified by the Kruskal-Wallis test then subtracting the grand mean of log2 fluorescence levels across patients for each peptide. Each point represents a patient, colored by clinical stage. (B) Volcano plots depicting peptides that met the 5% Benjamini-Hochberg (BH) false discovery rate (FDR) cut-off based on the Wilcoxon p values (horizontal lines) and had at least a twofold difference in median log2 fluorescence values between the stages being compared (vertical lines). The number of significantly increased peptides is shown on the right of each plot, the number of significantly decreased peptides is shown on the left, and the overall number of significantly changed peptides is shown at the top. Significant peptides are colored red. The left plot indicates peptides that had significantly different signals in patients with cancer compared with controls. The right plot indicates peptides that had significantly different signals in patients with mCRPC compared with all other groups. (C) Volcano plots indicating peptides that had significantly different signals between patients with consecutive clinical stages of disease. Box plots displaying fluorescence signals in (D) all patients with cancer compared with controls and (E) patients with nmCRPC compared with patients with nmCSPC in three example peptides that met both the twofold signal change and BH-adjusted p-value criteria. Box width is proportional to sample size. mCRPC, castration-resistant metastatic disease; nmCRPC, castration-resistant non-metastatic prostate cancer; nmCSPC, castration-sensitive non-metastatic prostate cancer.